By downregulating LDB1, the expression of LYL1, RUNX2, and other genes can be targeted, thereby regulating the malignant phenotype of AML through the promotion of apoptosis and inhibition of proliferation (Fig. 8E). Here, RUNX2 is linked to acute myeloid leukemia.